

# Luigi Mariani

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/578368/publications.pdf>

Version: 2024-02-01

380  
papers

30,971  
citations

5126

86  
h-index

6177

164  
g-index

385  
all docs

385  
docs citations

385  
times ranked

31019  
citing authors

#	ARTICLE	IF	CITATIONS
1	Uterine serous carcinoma: role of surgery, risk factors and oncologic outcomes. Experience of a tertiary center. <i>European Journal of Surgical Oncology</i> , 2022, 48, 268-274.	0.5	3
2	A Prospective Observational Study of Active Surveillance in Primary Desmoid Fibromatosis. <i>Clinical Cancer Research</i> , 2022, 28, 4027-4032.	3.2	21
3	Residual Adrenal Function After Multivisceral Resection With Adrenalectomy in Adult Patients. <i>JAMA Surgery</i> , 2022, , .	2.2	4
4	Cabozantinib as First-line Treatment in Patients With Metastatic Collecting Duct Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2022, 8, 910.	3.4	20
5	Oncological safety of selective axillary dissection after axillary reverse mapping in node-positive breast cancer. <i>European Journal of Surgical Oncology</i> , 2021, 47, 1606-1610.	0.5	7
6	Activity of sirolimus in patients with progressive epithelioid hemangioendothelioma: A caseâ€series analysis within the Italian Rare Cancer Network. <i>Cancer</i> , 2021, 127, 569-576.	2.0	24
7	Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients. , 2021, 9, e001167.		11
8	Systemic therapies in advanced epithelioid haemangioendothelioma: A retrospective international case series from the World Sarcoma Network and a review of literature. <i>Cancer Medicine</i> , 2021, 10, 2645-2659.	1.3	23
9	Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptorâ€Positive Advanced Breast Cancer (EVERMET). <i>Clinical Cancer Research</i> , 2021, 27, 3443-3455.	3.2	4
10	Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptorâ€Expressing Salivary Gland Cancer: A Phase II Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 4061-4068.	0.8	24
11	Systemic treatments in MDM2 positive intimal sarcoma: A multicentre experience with anthracycline, gemcitabine, and pazopanib within the World Sarcoma Network. <i>Cancer</i> , 2020, 126, 98-104.	2.0	25
12	Identifying an optimal lymph node yield for penile squamous cell carcinoma: prognostic impact of surgical dissection. <i>BJU International</i> , 2020, 125, 82-88.	1.3	20
13	Outpatient palliative care and thoracic medical oncology: Referral criteria and clinical care pathways. <i>Lung Cancer</i> , 2020, 139, 13-17.	0.9	4
14	Malnutrition and Perioperative Nutritional Support in Retroperitoneal Sarcoma Patients: Results from a Prospective Study. <i>Annals of Surgical Oncology</i> , 2020, 27, 2025-2032.	0.7	20
15	Hysteroscopic versus cervical injection for sentinel node detection in endometrial cancer: A multicenter prospective randomised controlled trial from the Multicenter Italian Trials in Ovarian cancer (MITO) study group. <i>European Journal of Cancer</i> , 2020, 140, 1-10.	1.3	18
16	Exercise Levels and Preferences in Cancer Patients: A Cross-Sectional Study. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 5351.	1.2	47
17	339P Impact of blood glucose levels on the efficacy of everolimus-exemestane in patients with advanced HR-positive/HER2 negative breast cancer: The EVERMET study. <i>Annals of Oncology</i> , 2020, 31, S382-S383.	0.6	0
18	Methadone for postoperative analgesia: contribution of N-methyl-d-aspartate receptor antagonism. <i>European Journal of Anaesthesiology</i> , 2020, 37, 934-943.	0.7	9

#	ARTICLE	IF	CITATIONS
19	Prognostic nomogram in patients with metastatic adenoid cystic carcinoma of the salivary glands. <i>European Journal of Cancer</i> , 2020, 136, 35-42.	1.3	27
20	The Activity of Chemotherapy in Inflammatory Myofibroblastic Tumors: A Multicenter, European Retrospective Case Series Analysis. <i>Oncologist</i> , 2020, 25, e1777-e1784.	1.9	27
21	Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 947-956.	5.1	166
22	Patients with adenoid cystic carcinomas of the salivary glands treated with lenvatinib: Activity and quality of life. <i>Cancer</i> , 2020, 126, 1888-1894.	2.0	54
23	Letter to the editor: a response to Mingâ€™s study on machine learning techniques for personalized breast cancer risk prediction. <i>Breast Cancer Research</i> , 2020, 22, 17.	2.2	4
24	Red clover and lifestyle changes to contrast menopausal symptoms in premenopausal patients with hormone-sensitive breast cancer receiving tamoxifen. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 157-165.	1.1	7
25	Prediction of contralateral breast cancer: external validation of risk calculators in 20 international cohorts. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 423-434.	1.1	14
26	The natural history of epithelioid sarcoma. A retrospective multicentre case-series within the Italian Sarcoma Group. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1320-1326.	0.5	17
27	EXPLORE EXERCISE LEVEL AND PREFERENCES IN PANCREATIC CANCER PATIENTS. <i>Medicine and Science in Sports and Exercise</i> , 2020, 52, 485-486.	0.2	0
28	An international study of the quality of life of adult patients treated with home parenteral nutrition. <i>Clinical Nutrition</i> , 2019, 38, 1788-1796.	2.3	51
29	Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study. <i>PLoS ONE</i> , 2019, 14, e0220644.	1.1	6
30	Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract. <i>Head and Neck</i> , 2019, 41, 3670-3676.	0.9	29
31	Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study. <i>Scientific Reports</i> , 2019, 9, 12993.	1.6	21
32	PO-165 Phase 2 study on axitinib in recurrent/metastatic salivary gland cancer of upper aerodigestive tract. <i>Radiotherapy and Oncology</i> , 2019, 132, 87-88.	0.3	0
33	Nomogram-based prediction of overall survival after regional lymph node dissection and the role of perioperative chemotherapy in penile squamous cell carcinoma: A retrospective multicenter study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2019, 37, 531.e7-531.e15.	0.8	27
34	Prediction and clinical utility of a contralateral breast cancer risk model. <i>Breast Cancer Research</i> , 2019, 21, 144.	2.2	24
35	An Open-label Randomized Phase 2 study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis. <i>European Urology</i> , 2019, 75, 201-203.	0.9	54
36	Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2019, 18, 34-43.e6.	1.0	7

#	ARTICLE	IF	CITATIONS
37	Activity of axitinib in progressive advanced solitary fibrous tumour: Results from an exploratory, investigator-driven phase 2 clinical study. <i>European Journal of Cancer</i> , 2019, 106, 225-233.	1.3	32
38	Prognostic factors in recurrent or metastatic squamous cell carcinoma of the head and neck. <i>Head and Neck</i> , 2019, 41, 1895-1902.	0.9	10
39	Lack of Effectiveness of Postchemotherapy Lymphadenectomy in Bladder Cancer Patients with Clinical Evidence of Metastatic Pelvic or Retroperitoneal Lymph Nodes Only: A Propensity Score-based Analysis. <i>European Urology Focus</i> , 2019, 5, 242-249.	1.6	11
40	Prognostic Effect of FGFR Mutations or Gene Fusions in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Results from a Large, Single-institution Cohort. <i>European Urology Focus</i> , 2019, 5, 853-856.	1.6	8
41	Predicting overall survival (OS) in patients (pts) with penile squamous cell carcinoma (PSCC) undergoing regional lymph node dissection (LND) ± multimodal therapy.. <i>Journal of Clinical Oncology</i> , 2019, 37, 512-512.	0.8	1
42	Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma. <i>JAMA Oncology</i> , 2018, 4, e180219.	3.4	63
43	Nutritional intervention in head and neck cancer patients during chemo-radiotherapy. <i>Nutrition</i> , 2018, 51-52, 95-97.	1.1	20
44	Secondary malignancies after high-dose chemotherapy in germ cell tumor patients: a 34-year retrospective study of the European Society for Blood and Marrow Transplantation (EBMT). <i>Bone Marrow Transplantation</i> , 2018, 53, 722-728.	1.3	5
45	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2018, 25, 607-618.	1.6	18
46	Urn models for response-adaptive randomized designs: a simulation study based on a non-adaptive randomized trial. <i>Journal of Biopharmaceutical Statistics</i> , 2018, 28, 1203-1215.	0.4	2
47	Association of Androgen Receptor Expression on Tumor Cells and PD-L1 Expression in Muscle-Invasive and Metastatic Urothelial Carcinoma: Insights for Clinical Research. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e403-e410.	0.9	11
48	Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study by the European Association of Urology “Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. <i>BJU International</i> , 2018, 121, 252-259.	1.3	61
49	First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study. <i>BJU International</i> , 2018, 121, 348-356.	1.3	70
50	Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: An open-label, single-arm, single-center, phase 2 study. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 8.e1-8.e8.	0.8	8
51	Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. <i>Journal of Clinical Oncology</i> , 2018, 36, 3353-3360.	0.8	474
52	Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study. <i>Cancer</i> , 2018, 124, 4056-4063.	2.0	40
53	Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?. <i>Breast</i> , 2018, 42, 68-73.	0.9	21
54	Impact of the Number of Cycles of Platinum Based First Line Chemotherapy for Advanced Urothelial Carcinoma. <i>Journal of Urology</i> , 2018, 200, 1207-1214.	0.2	26

#	ARTICLE	IF	CITATIONS
55	Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer. <i>European Journal of Cancer</i> , 2018, 97, 7-15.	1.3	34
56	Dynamics of the hazard for distant metastases after ipsilateral breast tumor recurrence according to estrogen receptor status: An analysis of 2851 patients. <i>Breast</i> , 2018, 40, 131-135.	0.9	3
57	Tumor-derived microRNAs induce myeloid suppressor cells and predict immunotherapy resistance in melanoma. <i>Journal of Clinical Investigation</i> , 2018, 128, 5505-5516.	3.9	193
58	Apache: An open label, randomized, phase 2 study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with advanced germ cell tumors (GCT): Results at the end of first stage.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4547-4547.	0.8	6
59	Phase II study on lenvatinib (LEN) in recurrent and/or metastatic (R/M) adenoid cystic carcinomas (ACC) of the salivary glands (SG) of the upper aerodigestive tract (NCT02860936).. <i>Journal of Clinical Oncology</i> , 2018, 36, 6086-6086.	0.8	7
60	Impact of number of cycles of platinum-based first-line chemotherapy for advanced urothelial carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 426-426.	0.8	3
61	Interim results from PURE-01: A phase 2, open-label study of neoadjuvant pembrolizumab (pembro) before radical cystectomy for muscle-invasive urothelial bladder carcinoma (MIUC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS533-TPS533.	0.8	4
62	PECULIAR: An open label, multicenter, single-arm, phase 2 study of neoadjuvant pembrolizumab (PEM) and epacadostat (EPA), preceding radical cystectomy (Cy), for patients (pts) with muscle-invasive urothelial bladder cancer (MIUBC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS534-TPS534.	0.8	5
63	Cabozantinib (CABO) plus durvalumab (DURVA) in patients with advanced and chemotherapy-treated bladder carcinoma of urothelial and non-urothelial histology: An open-label, single-arm, phase 2 trial.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS536-TPS536.	0.8	1
64	Effect of number of computed tomography (CT) scans during follow-up (FUP) of patients with clinical stage I (CSI) seminoma: A trial-level meta-analysis.. <i>Journal of Clinical Oncology</i> , 2018, 36, 564-564.	0.8	0
65	Abstract CT102: APACHE: An open label, randomized, phase II study of Durvalumab (Durva), alone or in combination with Tremelimumab (Treme), in patients (pts) with advanced germ cell tumors (GCT): Results at the end of first stage. <i>Cancer Research</i> , 2018, 78, CT102-CT102.	0.4	1
66	From the Uncertainties to the Evidence: A Brief History of Immunotherapy as Salvage Therapy for Advanced Bladder Cancer Through a Meta-analysis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 509-512.e9.	0.9	1
67	Soft tissue sarcoma nomograms and their incorporation into practice. <i>Cancer</i> , 2017, 123, 2802-2820.	2.0	105
68	Long-term Efficacy of Methotrexate Plus Vinblastine/Vinorelbine in a Large Series of Patients Affected by Desmoid-Type Fibromatosis. <i>Cancer Journal (Sudbury, Mass)</i> , 2017, 23, 86-91.	1.0	71
69	Pazopanib in advanced germ cell tumors after chemotherapy failure: results of the open-label, single-arm, phase 2 Pazotest trial. <i>Annals of Oncology</i> , 2017, 28, 1346-1351.	0.6	34
70	Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). <i>European Urology</i> , 2017, 71, 281-289.	0.9	56
71	MP34-13 NEOADJUVANT SORAFENIB, GEMCITABINE, AND CISPLATIN (SGC) FOR MUSCLE-INVASIVE UROTHELIAL BLADDER CANCER (MIUBC): FINAL RESULTS AND TRANSLATIONAL FINDINGS OF AN OPEN-LABEL, SINGLE-ARM, PHASE 2 STUDY.. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
72	Ten-year results of applying an original scoring system for addressing adjuvant therapy use after breast-conserving surgery for ductal carcinoma in situ of the breast. <i>Breast</i> , 2017, 35, 63-68.	0.9	5

#	ARTICLE	IF	CITATIONS
73	Effect of Bleomycin Administration on the Development of Pulmonary Toxicity in Patients With Metastatic Germ Cell Tumors Receiving First-Line Chemotherapy: A Meta-Analysis of Randomized Studies. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 213-220.e5.	0.9	27
74	Salvage High-Dose Chemotherapy for Relapsed Pure Seminoma in the Last 10 Years: Results From the European Society for Blood and Marrow Transplantation Series 2002-2012. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 163-167.	0.9	3
75	Methodological Considerations for Early-phase Development of Immune Checkpoint Inhibitors in Urothelial Bladder Cancer. <i>European Urology</i> , 2017, 71, 840-841.	0.9	0
76	FNA and CNB in the Diagnosis of Pulmonary Lesions: A Single-center Experience on 665 Patients, Comparison between Two Periods. <i>Tumori</i> , 2017, 103, 360-366.	0.6	5
77	Administration of high-dose chemotherapy with stem cell support in patients 40 years of age or older with advanced germ cell tumours: a retrospective study from the European Society for Blood and Marrow Transplantation database. <i>Bone Marrow Transplantation</i> , 2017, 52, 1218-1220.	1.3	4
78	Efficacy and safety of single agent pan-HER inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer (sSCC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 9543-9543.	0.8	5
79	CEA, CA15.3 and 18-FDG PET in the follow-up of early breast cancer (BC) patients (pts): A prospective, multicentric, randomized trialâ€”KRONOS patient-oriented new surveillance study Italy.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS11627-TPS11627.	0.8	3
80	Updated meta-analysis (MA) of salvage therapy for metastatic urothelial cancer (mUC): Comparing outcomes of immunotherapy (IT) versus single agent and doublet chemotherapy (CT).. <i>Journal of Clinical Oncology</i> , 2017, 35, 341-341.	0.8	2
81	Molecular features underlying response to neoadjuvant gemcitabine, cisplatin, and sorafenib (S-GC) in muscle-invasive urothelial bladder carcinoma (MIBC): Insights for trials of new agents combined with chemotherapy in the field.. <i>Journal of Clinical Oncology</i> , 2017, 35, e16018-e16018.	0.8	0
82	Frequent expression of androgen receptor (AR) on tumor cells of muscle-invasive (MIUC) and metastatic urothelial carcinoma (mUC): Insights for clinical research.. <i>Journal of Clinical Oncology</i> , 2017, 35, e16019-e16019.	0.8	0
83	Abstract CT139: First-line therapy with dacomitinib, an orally available pan-her tyrosine kinase inhibitor, for locally-advanced or metastatic penile squamous cell carcinoma: Results of an open label, single-arm, single-center, phase 2 study. , 2017, , .		0
84	Body Mass Index and Clinical Benefit of Fulvestrant in Postmenopausal Women with Advanced Breast Cancer. <i>Tumori</i> , 2016, 102, e11-e14.	0.6	18
85	Impact of home enteral nutrition in malnourished patients with upper gastrointestinal cancer: A multicentre randomised clinical trial. <i>European Journal of Cancer</i> , 2016, 64, 107-112.	1.3	60
86	The Long-Term Benefit of Liver Transplantation for Hepatic Metastases From Neuroendocrine Tumors. <i>American Journal of Transplantation</i> , 2016, 16, 2892-2902.	2.6	151
87	Propensity score analysis of outcomes following laparoscopic or open liver resection for hepatocellular carcinoma. <i>British Journal of Surgery</i> , 2016, 103, 871-880.	0.1	130
88	Drugâ€œeluting beads <i>versus</i> conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 645-653.	1.4	71
89	Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis. <i>Lancet Oncology</i> , The, 2016, 17, 671-680.	5.1	318
90	Interim 18F-Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Response to Cisplatin, Etoposide, and Bleomycin Chemotherapy for Metastatic Seminoma: Clinical Value and Future Directions. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 249-254.	0.9	12

#	ARTICLE	IF	CITATIONS
91	Prognostic Factors of Adjuvant Taxane, Cisplatin, and 5-Fluorouracil Chemotherapy for Patients With Penile Squamous Cell Carcinoma After Regional Lymphadenectomy. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 518-523.	0.9	28
92	The Sooner the Better? How Symptom Interval Correlates With Outcome in Children and Adolescents With Solid Tumors: Regression Tree Analysis of the Findings of a Prospective Study. <i>Pediatric Blood and Cancer</i> , 2016, 63, 479-485.	0.8	45
93	Salivary Cytokine Levels and Oral Mucositis in Head and Neck Cancer Patients Treated With Chemotherapy and Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 959-966.	0.4	48
94	A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact. <i>European Journal of Cancer</i> , 2016, 69, 158-165.	1.3	66
95	APACHE: An open label, randomized, phase 2 study of the anti-programmed death-ligand 1 (PD-L1) durvalumab (D, MEDI4736), alone or in combination with tremelimumab (T), in patients (pts) with advanced germ cell tumors (GCT). <i>Annals of Oncology</i> , 2016, 27, vi293.	0.6	1
96	Nomogram-based prediction of overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (UC) receiving first-line platinum-based chemotherapy: retrospective international study of invasive/advanced cancer of the urothelium (RISC). <i>Annals of Oncology</i> , 2016, 27, vi277.	0.6	0
97	GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study. <i>Journal of Translational Medicine</i> , 2016, 14, 125.	1.8	36
98	Performance and role of the breast lesion excision system (BLES) in small clusters of suspicious microcalcifications. <i>European Journal of Radiology</i> , 2016, 85, 143-149.	1.2	15
99	An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer. <i>Investigational New Drugs</i> , 2016, 34, 236-242.	1.2	21
100	Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. <i>Annals of Oncology</i> , 2016, 27, 49-61.	0.6	108
101	Panitumumab Treatment for Advanced Penile Squamous Cell Carcinoma When Surgery and Chemotherapy Have Failed. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 231-236.	0.9	38
102	The Changing Landscape of Intermediate- and Poor-Risk Germ Cell Tumors: Do We Need to Reclassify Patients With Metastatic Germ Cell Tumors?. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 1-4.	0.9	6
103	Osteopontin, E-cadherin, and $\beta$ -catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 412-420.	2.7	37
104	Pazopanib in patients (pts) with advanced germ cell tumors (GCT): Results from an open-label, single-group, phase 2 trial (Pazotest-01).. <i>Journal of Clinical Oncology</i> , 2016, 34, 481-481.	0.8	1
105	Prognostic factors of adjuvant chemotherapy with taxane, cisplatin, and 5FU combination (TPF) in patients (pts) with nodal metastases of penile squamous cell carcinoma (PSCC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 479-479.	0.8	2
106	A phase 2 study of the Aurora A kinase (AAK) tyrosine kinase inhibitor (TKI) alisertib (MLN8237) in patients (pts) with pretreated urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 382-382.	0.8	0
107	Pan-HER tyrosine-kinase inhibitors (TKI) dacomitinib and afatinib in penile squamous cell carcinoma (PSCC): Results from an ongoing open-label, single-group, phase 2 trial of dacomitinib in chemo-naïve patients (pts).. <i>Journal of Clinical Oncology</i> , 2016, 34, 483-483.	0.8	0
108	The RISC nomogram (RN) to predict overall survival (OS) of patients (pts) with metastatic urothelial carcinoma (mUC) receiving first-line platinum-based combination chemotherapy (CT).. <i>Journal of Clinical Oncology</i> , 2016, 34, e16026-e16026.	0.8	0

#	ARTICLE	IF	CITATIONS
109	Proposal of supervised data analysis strategy of plasma miRNAs from hybridisation array data with an application to assess hemolysis-related deregulation. <i>BMC Bioinformatics</i> , 2015, 16, 388.	1.2	16
110	Epidural analgesia does not influence anastomotic leakage incidence after open colorectal surgery for cancer: A retrospective study on 1,474 patients. <i>Journal of Surgical Oncology</i> , 2015, 112, 225-230.	0.8	13
111	Biological quality control for extracorporeal photochemotherapy: Assessing mononuclear cell apoptosis levels in ECP bags of chronic GvHD patients. <i>Journal of Clinical Apheresis</i> , 2015, 30, 162-170.	0.7	16
112	KIT, PDGFRA, and BRAF Mutational Spectrum Impacts on the Natural History of Imatinib-naive Localized GIST. <i>American Journal of Surgical Pathology</i> , 2015, 39, 922-930.	2.1	63
113	Hope in Cancer Patients: The Relational Domain as a Crucial Factor. <i>Tumori</i> , 2015, 101, 447-454.	0.6	25
114	Postchemotherapy Lymphadenectomy in Patients With Metastatic Urothelial Carcinoma: Long-Term Efficacy and Implications for Trial Design. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 80-86.e1.	0.9	17
115	Personalizing the Approach to Retroperitoneal Soft Tissue Sarcoma: Histology-specific Patterns of Failure and Postrelapse Outcome after Primary Extended Resection. <i>Annals of Surgical Oncology</i> , 2015, 22, 1447-1454.	0.7	152
116	Early oral nutrition after major pancreatic surgery. Author response to "Food at will after pancreaticoduodenectomies". <i>Nutrition</i> , 2015, 31, 1058-1059.	1.1	0
117	Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors: Implications for clinical practice, trial design, and molecular interrogation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 332.e19-332.e24.	0.8	12
118	Microenvironment-Modulated Metastatic CD133+/CXCR4+/EpCAM+ Lung Cancer "Initiating Cells Sustain Tumor Dissemination and Correlate with Poor Prognosis. <i>Cancer Research</i> , 2015, 75, 3636-3649.	0.4	83
119	Clinical Outcomes of Metastatic Poor Prognosis Germ Cell Tumors: Current Perspective From a Referral Center. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 385-391.e1.	0.9	4
120	Radiotherapy or chemotherapy for clinical stage IIA and IIB seminoma: a systematic review and meta-analysis of patient outcomes. <i>Annals of Oncology</i> , 2015, 26, 657-668.	0.6	71
121	Immunohistochemistry to Enhance Prognostic Allocation and Guide Decision-Making of Patients With Advanced Urothelial Cancer Receiving First-Line Chemotherapy. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 171-177.e1.	0.9	9
122	Development and validation of a nomogram to predict survival in incurable cachectic cancer patients on home parenteral nutrition. <i>Annals of Oncology</i> , 2015, 26, 2335-2340.	0.6	61
123	High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II study. <i>Annals of Oncology</i> , 2015, 26, 167-172.	0.6	17
124	A Prognostic Model Including Pre- and Postsurgical Variables to Enhance Risk Stratification of Primary Mediastinal Nonseminomatous Germ Cell Tumors: The 27-Year Experience of a Referral Center. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 87-93.e1.	0.9	27
125	Health and economic outcomes of two different follow up strategies in effectively cured advanced head and neck cancer patients. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS6625-TPS6625.	0.8	1
126	Interim [18f] fluorodeoxyglucose positron emission tomography (PET) for early metabolic assessment of response to PEB chemotherapy for metastatic seminoma: Preliminary findings. <i>Journal of Clinical Oncology</i> , 2015, 33, 381-381.	0.8	0



#	ARTICLE	IF	CITATIONS
127	Clinical outcomes of intermediate risk metastatic germ cell tumors (IRGCT): Results from a single-institution series.. Journal of Clinical Oncology, 2015, 33, 380-380.	0.8	0
128	Conventional-dose (CDCT) versus high-dose chemotherapy (HDCT) in the salvage management of relapsed pure seminoma: Results from an international database.. Journal of Clinical Oncology, 2015, 33, e15559-e15559.	0.8	0
129	Translational research on molecular markers in gastric cancer patients treated with adjuvant therapy (Italian Intergroup Adjuvant Chemotherapy of Adenocarcinoma of the Stomach-ITACA-S Trial).. Journal of Clinical Oncology, 2015, 33, e15016-e15016.	0.8	0
130	Single agent versus doublet chemotherapy as second-line therapy of metastatic urothelial carcinoma (UC): A meta-analysis.. Journal of Clinical Oncology, 2015, 33, e15527-e15527.	0.8	0
131	Prognostic reclassification of patients with intermediate risk metastatic germ cell tumors (IRGCT): implications for clinical practice, trial design, and molecular interrogation.. Journal of Clinical Oncology, 2015, 33, e15572-e15572.	0.8	0
132	Design of an open label, randomized, phase II study of paclitaxel and panitumumab compared to paclitaxel alone in patients with relapsed or refractory urothelial cancer.. Journal of Clinical Oncology, 2015, 33, TPS4570-TPS4570.	0.8	0
133	Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy. British Journal of Cancer, 2014, 110, 26-33.	2.9	16
134	<b><i>TP53</i></b> Mutations in Advanced Colorectal Cancer: The Dark Side of the Moon. Oncology, 2014, 86, 289-294.	0.9	10
135	Chronomodulated Capecitabine and Adjuvant Radiation in Intermediate-risk to High-risk Rectal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 545-549.	0.6	9
136	The prognosis of incurable cachectic cancer patients on home parenteral nutrition: a multi-centre observational study with prospective follow-up of 414 patients. Annals of Oncology, 2014, 25, 487-493.	0.6	71
137	Class II versus Class III radical hysterectomy in early cervical cancer: An observational study in a tertiary center. European Journal of Surgical Oncology, 2014, 40, 883-890.	0.5	14
138	Long-Term Efficacy and Safety Outcomes of Modified (Simplified) MVAC (Methotrexate/Vinblastine/Doxorubicin/Cisplatin) as Frontline Therapy for Unresectable or Metastatic Urothelial Cancer. Clinical Genitourinary Cancer, 2014, 12, 203-209.e1.	0.9	15
139	Treatment with tandem [90Y]DOTA-TATE and [177Lu]DOTA-TATE of neuroendocrine tumours refractory to conventional therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2014, 41, 223-230.	3.3	88
140	PF-03446962, a fully-human monoclonal antibody against transforming growth-factor $\beta^2$ (TGF $\beta^2$ ) receptor ALK1, in pre-treated patients with urothelial cancer: an open label, single-group, phase 2 trial. Investigational New Drugs, 2014, 32, 555-560.	1.2	50
141	Preoperative chemotherapy in advanced resectable OCSCC: long-term results of a randomized phase III trial. Annals of Oncology, 2014, 25, 462-466.	0.6	83
142	Prediction of Survival in Patients With Thin Melanoma: Results From a Multi-Institution Study. Journal of Clinical Oncology, 2014, 32, 2479-2485.	0.8	103
143	Treatment-related outcome of oropharyngeal cancer patients differentiated by HPV dictated risk profile: a tertiary cancer centre series analysis. Annals of Oncology, 2014, 25, 694-699.	0.6	33
144	Interim Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography for Early Metabolic Assessment of Therapeutic Response to Chemotherapy for Metastatic Transitional Cell Carcinoma. Clinical Genitourinary Cancer, 2014, 12, 433-439.	0.9	24

#	ARTICLE	IF	CITATIONS
145	Compliance of health professionals with the recommendations of the ESPEN Clinical Practice Guidelines: Results of ad hoc questionnaire. E-SPEN Journal, 2014, 9, e34-e38.	0.5	4
146	Perioperative nutritional support of patients undergoing pancreatic surgery in the age of ERAS. Nutrition, 2014, 30, 1267-1271.	1.1	55
147	MP50-16 A PANEL OF TISSUE BIOMARKERS EXPRESSION TO ENHANCE PROGNOSTIC STRATIFICATION IN LOCALLY-ADVANCED AND METASTATIC UROTHELIAL CANCERS (UC) UNDERGOING PERI-OPERATIVE AND FIRST-LINE PLATINUM-BASED CHEMOTHERAPY.. Journal of Urology, 2014, 191, .	0.2	0
148	Combination of Paclitaxel, Cisplatin, and Gemcitabine (TPG) for Multiple Relapses or Platinum-Resistant Germ Cell Tumors: Long-Term Outcomes. Clinical Genitourinary Cancer, 2014, 12, 63-69.e1.	0.9	27
149	An acceleromyographic train-of-four ratio of 1.0 reliably excludes respiratory muscle weakness after major abdominal surgery: a randomized double-blind study. Canadian Journal of Anaesthesia, 2014, 61, 641-649.	0.7	13
150	Expression of PD-L1 and NY-ESO-1 in early and advanced triple-negative breast cancer.. Journal of Clinical Oncology, 2014, 32, 1110-1110.	0.8	2
151	Enhancing risk stratification in primary mediastinal nonseminomatous germ cell tumors (PMNSGCT): A 27-year experience at a tertiary cancer center.. Journal of Clinical Oncology, 2014, 32, 373-373.	0.8	1
152	Predictive and prognostic significance of early positron emission tomography/computed tomography (PET/CT) in advanced transitional cell carcinoma.. Journal of Clinical Oncology, 2014, 32, 341-341.	0.8	0
153	Phase II study of neoadjuvant sorafenib plus cisplatin and gemcitabine (S-CG) for patients with muscle-invasive transitional cell carcinoma of the bladder (MIBC): Results at the end of first stage (NCT01222676).. Journal of Clinical Oncology, 2014, 32, 305-305.	0.8	0
154	Quantification and molecular profiling of circulating tumor cells (CTCs) in urothelial cancer (UC) before and during systemic treatment: Implications across the clinical stages.. Journal of Clinical Oncology, 2014, 32, 319-319.	0.8	0
155	Updated analysis of circulating tumor cells (CTCs) in patients with urothelial cancer (UC) undergoing systemic treatment: Implications across the clinical stages.. Journal of Clinical Oncology, 2014, 32, 4544-4544.	0.8	0
156	Nomograms to predict prognosis in pseudomyxoma peritonei: A Peritoneal Surface Oncology Group International (PSOGI) multicenter study.. Journal of Clinical Oncology, 2014, 32, 4033-4033.	0.8	0
157	Long-term results from INT-HER study: Retrospective evaluation of adjuvant trastuzumab in unselected HER2-positive breast cancer patientsâ€”Single institution experience.. Journal of Clinical Oncology, 2014, 32, e11509-e11509.	0.8	0
158	Development of a phase 2 study of the aurora kinase-A inhibitor alisertib (MLN8237) in pretreated patients (pts) with urothelial cancer (UC).. Journal of Clinical Oncology, 2014, 32, TPS4592-TPS4592.	0.8	0
159	Immunohistochemistry (IHC) to enhance the prognostic allocation of locally advanced and metastatic urothelial cancer (UC) undergoing first-line chemotherapy (CT).. Journal of Clinical Oncology, 2014, 32, 4547-4547.	0.8	0
160	Abstract 2852: SNAI2 expression by cancer-associated fibroblasts is a negative prognostic factor in non-small cell lung cancer. , 2014, , .		0
161	Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients. Clinical and Translational Oncology, 2013, 15, 582-586.	1.2	2
162	Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ cell tumors: long-term efficacy and safety outcomes. Annals of Oncology, 2013, 24, 2887-2892.	0.6	14

#	ARTICLE	IF	CITATIONS
163	Tp53 status as guide for the management of ethmoid sinus intestinal-type adenocarcinoma. Oral Oncology, 2013, 49, 413-419.	0.8	39
164	The Role of Lymphadenectomy in Cervical Cancer Patients: The Significance of the Number and the Status of Lymph Nodes Removed in 526 Cases Treated in a Single Institution. Annals of Surgical Oncology, 2013, 20, 3948-3954.	0.7	55
165	Response to chemotherapy of solitary fibrous tumour: A retrospective study. European Journal of Cancer, 2013, 49, 2376-2383.	1.3	77
166	747 MODIFIED CISPLATIN, ETOPOSIDE AND IFOSFAMIDE (PEI) SALVAGE THERAPY FOR MALE GERM-CELL TUMORS (GCT). LONG-TERM EFFICACY AND SAFETY OUTCOMES. Journal of Urology, 2013, 189, .	0.2	0
167	Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: A case-control study. Journal of Hepatology, 2013, 59, 59-66.	1.8	128
168	Prognostic Role of Pancreatic Metastases From Renal Cell Carcinoma: Results From an Italian Center. Clinical Genitourinary Cancer, 2013, 11, 484-488.	0.9	41
169	Persistent CD30 Expression by Embryonal Carcinoma in the Treatment Time Course: Prognostic Significance of a Worthwhile Target for Personalized Treatment. Journal of Urology, 2013, 190, 1919-1924.	0.2	36
170	Loss of Heterozygosity Analysis at Different Chromosome Regions in Wilms Tumor Confirms 1p Allelic Loss as a Marker of Worse Prognosis: A Study from the Italian Association of Pediatric Hematology and Oncology. Journal of Urology, 2013, 189, 260-267.	0.2	30
171	Resection of hepatocellular cancer >= 2 cm: Results from two Western centers. Hepatology, 2013, 57, 1426-1435.	3.6	326
172	Is the Standardized Uptake Value of FDG-PET/CT Predictive of Pathological Complete Response in Locally Advanced Rectal Cancer Treated with Capecitabine-Based Neoadjuvant Chemoradiation?. Oncology, 2013, 84, 191-199.	0.9	29
173	Phase II study on lapatinib in advanced EGFR-positive chordoma. Annals of Oncology, 2013, 24, 1931-1936.	0.6	122
174	Outcome Prediction in Primary Resected Retroperitoneal Soft Tissue Sarcoma: Histology-Specific Overall Survival and Disease-Free Survival Nomograms Built on Major Sarcoma Center Data Sets. Journal of Clinical Oncology, 2013, 31, 1649-1655.	0.8	268
175	Symptom interval in pediatric patients with solid tumors: Adolescents are at greater risk of late diagnosis. Pediatric Blood and Cancer, 2013, 60, 605-610.	0.8	49
176	Long-term efficacy and safety outcomes of the modified (simplified) combination of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) as front-line therapy for unresectable or metastatic urothelial cancer (UC).. Journal of Clinical Oncology, 2013, 31, 284-284.	0.8	0
177	High pathologic response rate of hepatic colorectal cancer metastases (HCRM) following neoadjuvant bevacizumab (Bev)-based treatment (tx).. Journal of Clinical Oncology, 2013, 31, 529-529.	0.8	1
178	Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ-cell tumors (GCT): Long-term efficacy and safety outcomes.. Journal of Clinical Oncology, 2013, 31, 328-328.	0.8	3
179	Abstract LB-320: Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer.. , 2013, , .		0
180	Abstract B33: Osteopontin expression is an independent poor prognostic marker in gastric cancer radically resected. Preliminary report of translational study of ITACA-S (Intergroup Trial of Adjuvant Tj ETQq0 0 0 rgBT /Overlœck 10 Tf 5		

#	ARTICLE	IF	CITATIONS
181	Frontline extended surgery is associated with improved survival in retroperitoneal low- to intermediate-grade soft tissue sarcomas. <i>Annals of Oncology</i> , 2012, 23, 1067-1073.	0.6	180
182	Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class II-Modified Peptides. <i>Clinical Cancer Research</i> , 2012, 18, 6485-6496.	3.2	61
183	New Directions for Biologic Targets in Urothelial Carcinoma – Letter. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2306-2306.	1.9	0
184	Tumor stage, human papillomavirus and smoking status affect the survival of patients with oropharyngeal cancer: an Italian validation study. <i>Annals of Oncology</i> , 2012, 23, 1832-1837.	0.6	97
185	Efficacy and tolerability of medical ozone gas insufflations in patients with osteonecrosis of the jaw treated with bisphosphonates – Preliminary data. <i>Journal of Bone Oncology</i> , 2012, 1, 81-87.	1.0	25
186	Diagnostic accuracy of sentinel node in endometrial cancer by using hysteroscopic injection of radiolabeled tracer. <i>Gynecologic Oncology</i> , 2012, 126, 419-423.	0.6	68
187	Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 810-816.	5.1	130
188	Leiomyosarcoma and sarcoma with myogenic differentiation. <i>Cancer</i> , 2012, 118, 5349-5357.	2.0	3
189	The nutritional risk in oncology: a study of 1,453 cancer outpatients. <i>Supportive Care in Cancer</i> , 2012, 20, 1919-1928.	1.0	142
190	Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. <i>Clinical and Experimental Nephrology</i> , 2012, 16, 464-467.	0.7	33
191	Weight loss in cancer patients: a plea for a better awareness of the issue. <i>Supportive Care in Cancer</i> , 2012, 20, 301-309.	1.0	51
192	Abstract LB-433: Biomarker analysis and final results of INT70/09 Phase II proof-of-concept study of Pazopanib (PZP) in refractory urothelial cancer (UC). , 2012, , .		2
193	Screening of related donors and peripheral blood stem cell collection practices at different Italian apheresis centres. <i>Blood Transfusion</i> , 2012, 10, 440-7.	0.3	13
194	Interleukin-8 (IL8) and transforming growth-factor beta (TGF- $\beta$ 2) as drugable biomarkers of response, progression-free survival (PFS), and overall survival (OS) with pazopanib (PZP): A phase II study in relapsed urothelial cancer (UC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 78-78.	0.8	0
195	Results of a Prospective Study Comparing Whole-Body Diffusion-Weighted Magnetic Resonance Imaging with Skeletal X-Ray and Magnetic Resonance of the Spine for Assessing Bone Disease in Multiple Myeloma.. <i>Blood</i> , 2012, 120, 2913-2913.	0.6	1
196	Non-metastatic unresected paediatric non-rhabdomyosarcoma soft tissue sarcomas: Results of a pooled analysis from United States and European groups. <i>European Journal of Cancer</i> , 2011, 47, 724-731.	1.3	123
197	Natural History of Imatinib-naïve GISTs. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1646-1656.	2.1	116
198	Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. <i>BJU International</i> , 2011, 108, 223-227.	1.3	10

#	ARTICLE	IF	CITATIONS
199	Efficacy and safety of medical ozone (O3) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: Preliminary results of a phase II study. <i>Oral Oncology</i> , 2011, 47, 185-190.	0.8	106
200	Myxofibrosarcoma: Prognostic Factors and Survival in a Series of Patients Treated at a Single Institution. <i>Annals of Surgical Oncology</i> , 2011, 18, 720-725.	0.7	199
201	Class III Nerve-sparing Radical Hysterectomy Versus Standard Class III Radical Hysterectomy: An Observational Study. <i>Annals of Surgical Oncology</i> , 2011, 18, 3469-3478.	0.7	45
202	Milan criteria in liver transplantation for hepatocellular carcinoma: An evidence-based analysis of 15 years of experience. <i>Liver Transplantation</i> , 2011, 17, S44-S57.	1.3	471
203	Intestinal type adenocarcinoma of the ethmoid sinus in wood and leather workers: A retrospective study of 153 cases. <i>Head and Neck</i> , 2011, 33, 535-542.	0.9	61
204	Myeloablative doses of yttrium-90-ibritumomab tiuxetan and the risk of secondary myelodysplasia/acute myelogenous leukemia. <i>Cancer</i> , 2011, 117, 5074-5084.	2.0	23
205	Survival Prediction for Terminally Ill Cancer Patients: Revision of the Palliative Prognostic Score with Incorporation of Delirium. <i>Oncologist</i> , 2011, 16, 1793-1799.	1.9	93
206	Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution. <i>Annals of Oncology</i> , 2011, 22, 1675-1681.	0.6	42
207	Spheres of Influence in Cancer Stem Cell Biology. <i>Journal of Investigative Dermatology</i> , 2011, 131, 546-547.	0.3	6
208	Breast change perception in women after smoking cessation. A pilot study. <i>Tumori</i> , 2011, 97, 672-5.	0.6	0
209	The symptom interval in children and adolescents with soft tissue sarcomas. <i>Cancer</i> , 2010, 116, 177-183.	2.0	66
210	Extremity Soft Tissue Sarcoma in a Series of Patients Treated at a Single Institution. <i>Annals of Surgery</i> , 2010, 251, 506-511.	2.1	253
211	Chordoma of the Mobile Spine and Sacrum: A Retrospective Analysis of a Series of Patients Surgically Treated at Two Referral Centers. <i>Annals of Surgical Oncology</i> , 2010, 17, 211-219.	0.7	159
212	Aggressive Surgery in Retroperitoneal Soft Tissue Sarcoma Carried Out at High-Volume Centers is Safe and is Associated With Improved Local Control. <i>Annals of Surgical Oncology</i> , 2010, 17, 1507-1514.	0.7	257
213	Histology-specific nomogram for primary retroperitoneal soft tissue sarcoma. <i>Cancer</i> , 2010, 116, 2429-2436.	2.0	93
214	Comparison of the Prognostic Value of Assessing Tumor Diameter Versus Tumor Volume at Diagnosis or in Response to Initial Chemotherapy in Rhabdomyosarcoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1322-1328.	0.8	58
215	Heterogeneous Phenotype of Human Melanoma Cells with In Vitro and In Vivo Features of Tumor-Initiating Cells. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1877-1886.	0.3	77
216	Soft Tissue Sarcomas of Childhood and Adolescence: The Prognostic Role of Tumor Size in Relation to Patient Body Size. <i>Journal of Clinical Oncology</i> , 2009, 27, 371-376.	0.8	55

#	ARTICLE	IF	CITATIONS
217	Pulmonary Nodules: Volume Repeatability at Multidetector CT Lung Cancer Screening. <i>Radiology</i> , 2009, 251, 919-925.	3.6	69
218	Plasma DNA Quantification in Lung Cancer Computed Tomography Screening. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009, 179, 69-74.	2.5	96
219	Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study. <i>Oral Oncology</i> , 2009, 45, 574-578.	0.8	184
220	Distal clearance margin of 1 cm or less: a safe distance in lower rectum cancer surgery. <i>International Journal of Colorectal Disease</i> , 2009, 24, 317-322.	1.0	45
221	Dose finding study of erlotinib combined to capecitabine and irinotecan in pretreated advanced colorectal cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 67-72.	1.1	8
222	Complementary and alternative medical therapies used by children with cancer treated at an Italian pediatric oncology unit. <i>Pediatric Blood and Cancer</i> , 2009, 53, 599-604.	0.8	36
223	No Salvage Using High-Dose Chemotherapy Plus/Minus Reirradiation for Relapsing Previously Irradiated Medulloblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1358-1363.	0.4	44
224	Desmoid-Type Fibromatosis: A Front-Line Conservative Approach to Select Patients for Surgical Treatment. <i>Annals of Surgical Oncology</i> , 2009, 16, 2587-2593.	0.7	334
225	Melanoma of the anorectal region. <i>European Journal of Surgical Oncology</i> , 2009, 35, 757-762.	0.5	70
226	Plasma DNA levels in spiral CT-detected and clinically detected lung cancer patients: A validation analysis. <i>Lung Cancer</i> , 2009, 66, 270-271.	0.9	7
227	Defining and Classifying Cancer Cachexia: A Proposal by the SCRINIO Working Group. <i>Journal of Parenteral and Enteral Nutrition</i> , 2009, 33, 361-367.	1.3	124
228	Aggressive Surgical Policies in a Retrospectively Reviewed Single-Institution Case Series of Retroperitoneal Soft Tissue Sarcoma Patients. <i>Journal of Clinical Oncology</i> , 2009, 27, 24-30.	0.8	410
229	Serial determination of CEA and CA 15.3 in breast cancer follow-up: An assessment of their diagnostic accuracy for the detection of tumour recurrences. <i>Biomarkers</i> , 2009, 14, 130-136.	0.9	29
230	Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. <i>Lancet Oncology</i> , The, 2009, 10, 35-43.	5.1	1,920
231	Highly tumorigenic lung cancer CD133 <sup>+</sup> cells display stem-like features and are spared by cisplatin treatment. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 16281-16286.	3.3	733
232	Polymorphisms of Metabolizing Enzymes and Susceptibility to Ethmoid Intestinal-type Adenocarcinoma in Professionally Exposed Patients. <i>Translational Oncology</i> , 2009, 2, 84-88.	1.7	9
233	Perioperative Intravenous Glutamine Supplementatation in Major Abdominal Surgery for Cancer. <i>Annals of Surgery</i> , 2009, 250, 684-690.	2.1	47
234	Fluorodeoxyglucose Uptake Measured by Positron Emission Tomography and Standardized Uptake Value Predicts Long-Term Survival of CT Screening Detected Lung Cancer in Heavy Smokers. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1352-1356.	0.5	30

#	ARTICLE	IF	CITATIONS
235	The prognostic impact of dedifferentiation in retroperitoneal liposarcoma. <i>Cancer</i> , 2008, 113, 1657-1665.	2.0	81
236	Role of sonoelastography in non-palpable breast lesions. <i>European Radiology</i> , 2008, 18, 2381-2389.	2.3	147
237	Cyclin D1 expression analysis in familial breast cancers may discriminate BRCA1 from BRCA2-linked cases. <i>Modern Pathology</i> , 2008, 21, 1262-1270.	2.9	16
238	Computer-assisted image analysis of breast fine needle aspiration in a randomized chemoprevention trial of fenretinide vs. placebo in HRT users. <i>Breast</i> , 2008, 17, 91-97.	0.9	1
239	Penoscopically Controlled CO <sub>2</sub> Laser Excision for Conservative Treatment of In Situ and T1 Penile Carcinoma: Report on 224 Patients. <i>European Urology</i> , 2008, 54, 875-884.	0.9	115
240	Rebuttal from Authors re: Simon Horenblas. Editorial Comment on: Peniscopically Controlled CO <sub>2</sub> Laser Excision for Conservative Treatment of In Situ and T1 Penile Carcinoma: Report on 224 Patients. <i>European Urology</i> , 2008, 54, 883-884.	0.9	1
241	Lymph Node Metastases in Malignant Tumors of the Paranasal Sinuses. <i>JAMA Otolaryngology</i> , 2008, 134, 170.	1.5	139
242	FHIT and p53 Status and Response to Platinum-Based Treatment in Advanced Non-Small Cell Lung Cancer. <i>Current Cancer Drug Targets</i> , 2008, 8, 342-348.	0.8	12
243	Lung Cancer Stage is an Independent Risk Factor for Surgical Mortality. <i>Tumori</i> , 2008, 94, 362-369.	0.6	6
244	A double-blind, randomised, vehicle-controlled clinical study to evaluate the efficacy of MAS065D in limiting the effects of radiation on the skin: interim analysis. <i>European Journal of Dermatology</i> , 2008, 18, 317-21.	0.3	30
245	Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study. <i>British Journal of Cancer</i> , 2007, 96, 439-444.	2.9	34
246	Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study. <i>Annals of Oncology</i> , 2007, 18, 461-467.	0.6	31
247	Evaluation of LRRK2 G2019S penetrance: Relevance for genetic counseling in Parkinson disease. <i>Neurology</i> , 2007, 68, 1141-1143.	1.5	141
248	Identification of a New Subset of Myeloid Suppressor Cells in Peripheral Blood of Melanoma Patients With Modulation by a Granulocyte-Macrophage Colony-Stimulation Factor- $\alpha$ -Based Antitumor Vaccine. <i>Journal of Clinical Oncology</i> , 2007, 25, 2546-2553.	0.8	606
249	Adult-type soft tissue sarcomas in paediatric age: A nomogram-based prognostic comparison with adult sarcoma. <i>European Journal of Cancer</i> , 2007, 43, 2691-2697.	1.3	43
250	Short-term effects of pamidronate on bone turnover: Can bone markers be considered predictive of the analgesic response?. <i>Oncology Reports</i> , 2007, 17, 1533-40.	1.2	6
251	p53 codon 72 polymorphisms in human papillomavirus-negative and human papillomavirus-positive squamous cell carcinomas of the oropharynx. <i>Cancer</i> , 2007, 109, 2461-2465.	2.0	31
252	Myxoid/round cell and pleomorphic liposarcomas. <i>Cancer</i> , 2007, 109, 2522-2531.	2.0	145

#	ARTICLE	IF	CITATIONS
253	Thyroid disorders in patients treated with radiotherapy for head-and-neck cancer: A retrospective analysis of seventy-three patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 144-150.	0.4	98
254	Postoperative complications in gastrointestinal cancer patients: The joint role of the nutritional status and the nutritional support. <i>Clinical Nutrition</i> , 2007, 26, 698-709.	2.3	320
255	Estimation of predictive accuracy in survival analysis using R and S-PLUS. <i>Computer Methods and Programs in Biomedicine</i> , 2007, 87, 132-137.	2.6	21
256	Advanced Extremity Soft Tissue Sarcoma: Prognostic Effect of Isolated Limb Perfusion in a Series of 88 Patients Treated at a Single Institution. <i>Annals of Surgical Oncology</i> , 2007, 14, 553-559.	0.7	61
257	Extremity Soft Tissue Sarcoma: Adding to the Prognostic Meaning of Local Failure. <i>Annals of Surgical Oncology</i> , 2007, 14, 1583-1590.	0.7	70
258	Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. <i>Breast Cancer Research and Treatment</i> , 2007, 101, 355-365.	1.1	130
259	Influence of Antibiotic Treatment on Breast Carcinoma Development in Proto-neu Transgenic Mice. <i>Cancer Research</i> , 2006, 66, 6219-6224.	0.4	43
260	Linking survival of HER2-positive breast carcinoma patients with surgical invasiveness. <i>European Journal of Cancer</i> , 2006, 42, 1057-1061.	1.3	8
261	Cytoreduction combined with intraperitoneal hyperthermic perfusion chemotherapy in advanced/recurrent ovarian cancer patients: The experience of National Cancer Institute of Milan. <i>European Journal of Surgical Oncology</i> , 2006, 32, 671-675.	0.5	105
262	Quality of life assessment in a chemoprevention trial: Fenretinide and oral or transdermal HRT. <i>Maturitas</i> , 2006, 55, 69-75.	1.0	5
263	Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer. <i>Oncology Reports</i> , 2006, 16, 393.	1.2	1
264	Clinical Application of Spectral Electromagnetic Interaction in Breast Cancer: Diagnostic Results of a Pilot Study. <i>Tumori</i> , 2006, 92, 207-212.	0.6	9
265	Irinotecan, Fluorouracil and Folinic ACID (FOLFIRI) as Effective Treatment Combination for Patients with Advanced Gastric Cancer in Poor Clinical Condition. <i>Tumori</i> , 2006, 92, 379-383.	0.6	11
266	Capecitabine Chemoradiation for Rectal Cancer after Curative Surgery. <i>Journal of Chemotherapy</i> , 2006, 18, 85-89.	0.7	7
267	Tetracaine oral gel in patients treated with radiotherapy for head-and-neck cancer: Final results of a phase II study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 392-395.	0.4	15
268	Prognostic Effect of Re-Excision in Adult Soft Tissue Sarcoma of the Extremity. <i>Annals of Surgical Oncology</i> , 2006, 13, 110-117.	0.7	141
269	A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Cp96, in combination with GM-CSF and interferon- $\gamma$ in metastatic melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 958-968.	2.0	134
270	Pathological features as predictors of recurrence after radical resection of gastric cancer. <i>British Journal of Surgery</i> , 2006, 93, 205-209.	0.1	45



#	ARTICLE	IF	CITATIONS
271	Malignant peripheral nerve sheath tumors. <i>Cancer</i> , 2006, 107, 1065-1074.	2.0	358
272	Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. <i>Hepatology</i> , 2006, 44, 1543-1554.	3.6	347
273	Methylation profile in tumor and sputum samples of lung cancer patients detected by spiral computed tomography: A nested case-control study. <i>International Journal of Cancer</i> , 2006, 118, 1248-1253.	2.3	49
274	Feasibility of Sequential Therapy with FOLFIRI Followed by Docetaxel/Cisplatin in Patients with Radically Resected Gastric Adenocarcinoma. <i>Oncology</i> , 2006, 71, 341-346.	0.9	15
275	Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer. <i>Annals of Oncology</i> , 2006, 17, 1065-1071.	0.6	187
276	Telomere Maintenance Mechanisms in Liposarcomas: Association with Histologic Subtypes and Disease Progression. <i>Cancer Research</i> , 2006, 66, 8918-8924.	0.4	115
277	High-Risk Human Papillomavirus Affects Prognosis in Patients With Surgically Treated Oropharyngeal Squamous Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 5630-5636.	0.8	605
278	Role of Home Parenteral Nutrition in Chronic Radiation Enteritis. <i>American Journal of Gastroenterology</i> , 2006, 101, 374-379.	0.2	36
279	The Combination of the Selective Cyclooxygenase-2 Inhibitor Celecoxib with Weekly Paclitaxel Is a Safe and Active Second-Line Therapy for Non-Small Cell Lung Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2005, 11, 209-216.	1.0	31
280	Pulsed Dose-Rate Perioperative Interstitial Brachytherapy for Soft Tissue Sarcomas of the Extremities and Skeletal Muscles of the Trunk. <i>Annals of Surgical Oncology</i> , 2005, 12, 935-942.	0.7	17
281	CpG-oligodeoxynucleotides induce mobilization of hematopoietic progenitor cells into peripheral blood in association with mouse KC (IL-8) production. <i>Journal of Cellular Physiology</i> , 2005, 204, 889-895.	2.0	26
282	Which classification for ethmoid malignant tumors involving the anterior skull base?. <i>Head and Neck</i> , 2005, 27, 224-231.	0.9	19
283	Validation and adaptation of a nomogram for predicting the survival of patients with extremity soft tissue sarcoma using a three-grade system. <i>Cancer</i> , 2005, 103, 402-408.	2.0	182
284	Perception that Oral Anticancer Treatments are Less Efficacious: Development of a Questionnaire to Assess the Possible Prejudices of Patients with Cancer. <i>Breast Cancer Research and Treatment</i> , 2005, 92, 265-272.	1.1	49
285	A Modified Prognostic Score for Patients with Curatively Resected Gastric Cancer. <i>Tumori</i> , 2005, 91, 221-226.	0.6	5
286	Combined Therapy with Weekly Irinotecan, Infusional 5-Fluorouracil and the Selective COX-2 Inhibitor Rofecoxib Is a Safe and Effective Second-Line Treatment in Metastatic Colorectal Cancer. <i>Oncologist</i> , 2005, 10, 710-717.	1.9	24
287	Adult-Type Soft Tissue Sarcomas in Pediatric-Age Patients: Experience at the Istituto Nazionale Tumori in Milan. <i>Journal of Clinical Oncology</i> , 2005, 23, 4021-4030.	0.8	130
288	Effects of Prolonged Storage of Whole Plasma or Isolated Plasma DNA on the Results of Circulating DNA Quantification Assays. <i>Journal of the National Cancer Institute</i> , 2005, 97, 1848-1850.	3.0	144

#	ARTICLE	IF	CITATIONS
289	Dermatofibrosarcoma Protuberans Treated at a Single Institution: A Surgical Disease With a High Cure Rate. <i>Journal of Clinical Oncology</i> , 2005, 23, 7669-7675.	0.8	196
290	Status of Surgical Margins and Prognosis in Adult Soft Tissue Sarcomas of the Extremities: A Series of Patients Treated at a Single Institution. <i>Journal of Clinical Oncology</i> , 2005, 23, 96-104.	0.8	248
291	Safety and Efficacy of Two Different Doses of Capecitabine in the Treatment of Advanced Breast Cancer in Older Women. <i>Journal of Clinical Oncology</i> , 2005, 23, 2155-2161.	0.8	200
292	Reduced FEZ1/LZTS1 Expression and Outcome Prediction in Lung Cancer. <i>Cancer Research</i> , 2005, 65, 1207-1212.	0.4	33
293	Natural Killer and NK-Like T-Cell Activation in Colorectal Carcinoma Patients Treated with Autologous Tumor-Derived Heat Shock Protein 96. <i>Cancer Research</i> , 2005, 65, 3942-3949.	0.4	47
294	Is the new WHO classification of neuroendocrine tumours useful for selecting an appropriate treatment?. <i>Annals of Oncology</i> , 2005, 16, 1374-1380.	0.6	67
295	p53 Gene Status and Response to Topotecan-Containing Chemotherapy in Advanced Ovarian Carcinoma. <i>Oncology</i> , 2005, 69, 154-158.	0.9	5
296	Sentinel node biopsy in breast cancer: early results in 953 patients with negative sentinel node biopsy and no axillary dissection. <i>European Journal of Cancer</i> , 2005, 41, 231-237.	1.3	163
297	Revising a Prognostic Index Developed for Classification Purposes: An Application to Gastric Cancer Data. <i>Journal of Applied Statistics</i> , 2004, 31, 817-830.	0.6	9
298	Prospective evaluation of estrogen receptor- $\beta^2$ in predicting response to neoadjuvant antiestrogen therapy in elderly breast cancer patients. <i>Endocrine-Related Cancer</i> , 2004, 11, 761-770.	1.6	25
299	Prediction of TP53 Status for Primary Cisplatin, Fluorouracil, and Leucovorin Chemotherapy in Ethmoid Sinus Intestinal-Type Adenocarcinoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 4901-4906.	0.8	99
300	Glucose-based total parenteral nutrition does not stimulate glucose uptake by humans tumours. <i>Clinical Nutrition</i> , 2004, 23, 417-421.	2.3	35
301	Safety and Activity of the Combination of Pegylated Liposomal Doxorubicin and Weekly Docetaxel in Advanced Breast Cancer. <i>Breast Cancer Research and Treatment</i> , 2004, 86, 249-258.	1.1	27
302	Randomized multicenter Phase II trial of two different schedules of irinotecan combined with capecitabine as first-line treatment in metastatic colorectal carcinoma. <i>Cancer</i> , 2004, 100, 279-287.	2.0	134
303	Retroperitoneal soft tissue sarcomas. <i>Cancer</i> , 2004, 100, 2448-2455.	2.0	167
304	Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution. <i>Cancer</i> , 2004, 101, 905-912.	2.0	64
305	Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2004, 43, 203-208.	0.9	12
306	Radiofrequency Ablation of Small Hepatocellular Carcinoma in Cirrhotic Patients Awaiting Liver Transplantation. <i>Annals of Surgery</i> , 2004, 240, 900-909.	2.1	452

#	ARTICLE	IF	CITATIONS
307	Evaluation of reactive oxygen metabolites in frozen serum samples. Effect of storage and repeated thawing. <i>International Journal of Biological Markers</i> , 2004, 19, 250-253.	0.7	16
308	Gynaecomastia in men with chronic myeloid leukaemia after imatinib. <i>Lancet, The</i> , 2003, 361, 1954-1956.	6.3	88
309	A Novel Intraarterial Chemotherapy Using Paclitaxel in Albumin Nanoparticles to Treat Advanced Squamous Cell Carcinoma of the Tongue: Preliminary Findings. <i>American Journal of Roentgenology</i> , 2003, 181, 253-260.	1.0	75
310	Primary Chemotherapy in Resectable Oral Cavity Squamous Cell Cancer: A Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2003, 21, 327-333.	0.8	240
311	Quality of Surgery and Outcome in Extra-Abdominal Aggressive Fibromatosis: A Series of Patients Surgically Treated at a Single Institution. <i>Journal of Clinical Oncology</i> , 2003, 21, 1390-1397.	0.8	326
312	Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer. <i>Annals of Oncology</i> , 2003, 14, 242-247.	0.6	16
313	Postoperative starvation after gastrointestinal surgery. <i>BMJ: British Medical Journal</i> , 2002, 324, 481-481.	2.4	0
314	Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group. <i>Annals of Oncology</i> , 2002, 13, 299-307.	0.6	131
315	Twenty-Year Follow-up of a Randomized Study Comparing Breast-Conserving Surgery with Radical Mastectomy for Early Breast Cancer. <i>New England Journal of Medicine</i> , 2002, 347, 1227-1232.	13.9	3,765
316	c-erbB 2 Serum level as prognostic factor in hormonally treated advanced breast cancer patients. <i>Breast</i> , 2002, 11, 286-294.	0.9	0
317	Central venous catheter complications in 447 patients on home parenteral nutrition: an analysis of over 100.000 catheter days. <i>Clinical Nutrition</i> , 2002, 21, 475-485.	2.3	118
318	Preoperative chemoradiation in patients with resectable rectal cancer: Results on tumor response. <i>Annals of Surgical Oncology</i> , 2002, 9, 444-449.	0.7	28
319	Effect of Fenretinide on Ovarian Carcinoma Occurrence. <i>Gynecologic Oncology</i> , 2002, 86, 24-27.	0.6	86
320	Preoperative chemoradiation in patients with resectable rectal cancer: Results on tumor response. , 2002, 9, 444.		1
321	Postoperative enteral versus parenteral nutrition in malnourished patients with gastrointestinal cancer: a randomised multicentre trial. <i>Lancet, The</i> , 2001, 358, 1487-1492.	6.3	444
322	Safety of the Synthetic Retinoid Fenretinide: Long-Term Results From a Controlled Clinical Trial for the Prevention of Contralateral Breast Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 1664-1670.	0.8	97
323	Radiotherapy after breast-conserving surgery in small breast carcinoma: Long-term results of a randomized trial. <i>Annals of Oncology</i> , 2001, 12, 997-1003.	0.6	650
324	SYT-SSX fusion genes and prognosis in synovial sarcoma. <i>British Journal of Cancer</i> , 2001, 85, 1535-1539.	2.9	56

#	ARTICLE	IF	CITATIONS
325	Re: Randomized Trial of Fenretinide to Prevent Second Breast Malignancy in Women With Early Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2001, 93, 240-241.	3.0	9
326	Gemcitabine plus vinorelbine as first-line chemotherapy in advanced nonsmall cell lung carcinoma a Phase II trial. <i>Cancer</i> , 2000, 89, 763-768.	2.0	28
327	Content and Quality of Currently Published Phase II Cancer Trials. <i>Journal of Clinical Oncology</i> , 2000, 18, 429-429.	0.8	50
328	Double-Contrast Barium Enema and Computerised Tomography in the Pre-Operative Evaluation of Rectal Carcinoma: Are they Still Useful Diagnostic Procedures?. <i>Tumori</i> , 2000, 86, 389-392.	0.6	13
329	Relationships between age, mammographic features and pathological tumour characteristics in non-palpable breast cancer.. <i>British Journal of Radiology</i> , 2000, 73, 698-705.	1.0	49
330	Re: Vitamin A Analogue for Breast Cancer Prevention: a Grade of F or Incomplete?. <i>Journal of the National Cancer Institute</i> , 2000, 92, 274-274.	3.0	1
331	Perioperative Total Parenteral Nutrition in Malnourished, Gastrointestinal Cancer Patients: A Randomized, Clinical Trial. <i>Journal of Parenteral and Enteral Nutrition</i> , 2000, 24, 7-14.	1.3	226
332	The luteinising hormoneâ€“releasing hormone analogue triptorelin with or without the aromatase inhibitor formestane in premenopausal breast cancer: effects on bone metabolism markers. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2000, 75, 65-73.	1.2	7
333	Early Gastric Cancer: Unrecognized Indicator of Multiple Malignancies. <i>World Journal of Surgery</i> , 2000, 24, 583-587.	0.8	10
334	Accrual Issues for Chemoprevention Trials: The Example of the 4-HPR Study for the Prevention of Contralateral Breast Cancer. <i>Tumori</i> , 1999, 85, 299-303.	0.6	4
335	Randomized Trial of Fenretinide to Prevent Second Breast Malignancy in Women With Early Breast Cancer. <i>Journal of the National Cancer Institute</i> , 1999, 91, 1847-1856.	3.0	375
336	Artificial Nutrition in Cancer Patients: Which Route, What Composition?. <i>World Journal of Surgery</i> , 1999, 23, 577-583.	0.8	27
337	Preoperative radiation therapy for patients with T2-T3 carcinoma of the middle-to-lower rectum. , 1999, 86, 398-404.		43
338	Anterior craniofacial resection for malignant ethmoid tumors?A series of 91 patients. , 1999, 21, 185-191.		90
339	The dissection of internal mammary nodes does not improve the survival of breast cancer patients. 30-year results of a randomised trial. <i>European Journal of Cancer</i> , 1999, 35, 1320-1325.	1.3	333
340	Expression of Angiogenesis Stimulators and Inhibitors in Human Thyroid Tumors and Correlation with Clinical Pathological Features. <i>American Journal of Pathology</i> , 1999, 155, 1967-1976.	1.9	364
341	A New Classification for Malignant Tumors Involving the Anterior Skull Base. <i>JAMA Otolaryngology</i> , 1999, 125, 1252.	1.5	44
342	FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) study. <i>British Journal of Cancer</i> , 1998, 77, 1149-1154.	2.9	7

#	ARTICLE	IF	CITATIONS
343	5-fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. , 1998, 83, 372-378.		139
344	Oral doxifluridine plus levoleucovorin in elderly patients with advanced breast cancer. Cancer, 1998, 83, 1136-1141.	2.0	14
345	Feed forward neural networks for the analysis of censored survival data: a partial logistic regression approach. , 1998, 17, 1169-1186.		202
346	Is steroid receptor profile in contralateral breast cancer a marker of independence of the corresponding primary tumour?. European Journal of Cancer, 1998, 34, 825-830.	1.3	46
347	Ten year results of a randomised trial comparing two conservative treatment strategies for small size breast cancer. European Journal of Cancer, 1998, 34, 1156-1162.	1.3	68
348	Early breast cancer: evaluation of the prognostic role of the site of the primary tumor.. Journal of Clinical Oncology, 1998, 16, 1363-1366.	0.8	82
349	Can bone metabolism markers be adopted as an alternative to scintigraphic imaging in monitoring bone metastases from breast cancer?. European Journal of Nuclear Medicine and Molecular Imaging, 1997, 24, 1349-1355.	3.3	20
350	The aromatase inhibitor letrozole in advanced breast cancer: Effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels. Journal of Steroid Biochemistry and Molecular Biology, 1997, 63, 261-267.	1.2	33
351	The minimal effective exemestane dose for endocrine activity in advanced breast cancer. European Journal of Cancer, 1997, 33, 587-591.	1.3	38
352	Impact of Distal Clearance Margin on Oncologic Outcome after Restorative Resection of the Rectum. Tumori, 1997, 83, 907-911.	0.6	9
353	Chemoprevention Trial of Contralateral Breast Cancer with Fenretinide. Rationale, Design, Methodology, Organization, Data Management, Statistics and Accrual. Tumori, 1997, 83, 884-894.	0.6	32
354	Prognostic factors for metachronous contralateral breast cancer: A comparison of the linear Cox regression model and its artificial neural network extension. Breast Cancer Research and Treatment, 1997, 44, 167-178.	1.1	63
355	Insular Carcinoma. American Journal of Surgical Pathology, 1997, 21, 1466-1473.	2.1	109
356	New method for expressing survival in cancer. BMJ: British Medical Journal, 1997, 315, 1375-1375.	2.4	1
357	Results of a breast-cancer-surgery trial compared with observational data from routine practice. Lancet, The, 1996, 347, 1000-1003.	6.3	31
358	Chemoprevention of Breast Cancer with Fenretinide (4-HPR): Study of Long-Term Visual and Ophthalmologic Tolerability. Tumori, 1996, 82, 444-449.	0.6	29
359	Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease.. Journal of Clinical Oncology, 1996, 14, 2546-2551.	0.8	126
360	Non-small-cell lung cancer: detection of mediastinal lymph node metastases by endoscopic ultrasound and CT. European Radiology, 1996, 6, 19-24.	2.3	19

#	ARTICLE	IF	CITATIONS
361	Cancer of the low and middle rectum: Local and distant recurrences, and survival in 350 radically resected patients. , 1996, 62, 207-213.		32
362	Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors: A study by the Italian Trials in Medical Oncology group. , 1996, 77, 402-408.		257
363	A dose-finding study of lanreotide (A somatostatin analog) in patients with colorectal carcinoma. , 1996, 78, 35-42.		6
364	Gene expression of DNA topoisomerases I, III $\alpha$ and III $\beta$ and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. , 1996, 67, 479-484.		19
365	Age-related activation of the tyrosine kinase receptor protooncogenes RET and NTRK1 in papillary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism, 1996, 81, 2006-2009.	1.8	130
366	Combination goserelin and tamoxifen therapy in premenopausal advanced breast cancer: a multicentre study by the ITMO group. British Journal of Cancer, 1995, 71, 1111-1114.	2.9	15
367	Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor. British Journal of Cancer, 1995, 72, 1007-1012.	2.9	74
368	Controlled clinical trials with fenretinide in breast cancer, basal cell carcinoma and oral leukoplakia. Journal of Cellular Biochemistry, 1995, 59, 11-17.	1.2	58
369	The influence of radiotherapy on cosmetic outcome after breast conservative surgery. International Journal of Radiation Oncology Biology Physics, 1995, 33, 59-64.	0.4	37
370	Breast conservation is a safe method in patients with small cancer of the breast. Long-term results of three randomised trials on 1,973 patients. European Journal of Cancer, 1995, 31, 1574-1579.	1.3	417
371	An I.T.M.O. group study on second-line treatment in advanced epithelial ovarian cancer: an attempt to identify clinical and biological factors determining prognosis. European Journal of Cancer, 1995, 31, 2248-2254.	1.3	12
372	Effect of menstrual phase on surgical treatment of breast cancer. Lancet, The, 1994, 343, 1545-1547.	6.3	107
373	Pain measurement in cancer patients: a comparison of six methods. Pain, 1994, 57, 161-166.	2.0	136
374	Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a: A study by the Italian trials in Medical Oncology Group. Cancer, 1993, 72, 3099-3105.	2.0	121
375	Fenretinide (4-HPR) in chemoprevention of oral leukoplakia. Journal of Cellular Biochemistry, 1993, 53, 255-261.	1.2	62
376	Experimental and nonexperimental studies: Methodological, ethical, and practical implications in the context of hepatobiliary tumors. Journal of Surgical Oncology, 1993, 53, 181-185.	0.8	0
377	Prevention of local relapses and new localisations of oral leukoplakias with the synthetic retinoid fenretinide (4-HPR). Preliminary results. European Journal of Cancer Part B, Oral Oncology, 1992, 28, 97-102.	0.9	93
378	Long-term tolerability of fenretinide (4-HPR) in breast cancer patients. European Journal of Cancer & Clinical Oncology, 1991, 27, 1127-1131.	0.9	97

#	ARTICLE	IF	CITATIONS
379	3H-thymidine-labeling index as a prognostic indicator in node-positive breast cancer.. Journal of Clinical Oncology, 1990, 8, 1321-1326.	0.8	56
380	Clinically Useful Measures to Assess the Effectiveness of Treatments: Hints for a Proper Choice with Special Emphasis on Cancer Research. Tumori, 1990, 76, 1-9.	0.6	4